Back to top
more

United Therapeutics (UTHR)

(Real Time Quote from BATS)

$302.85 USD

302.85
95,549

+3.43 (1.15%)

Updated Aug 8, 2025 11:38 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (77 out of 244)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why United Therapeutics (UTHR) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Ionis Pharmaceuticals (IONS) Down 0.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why Is United Therapeutics (UTHR) Up 4.8% Since Last Earnings Report?

by Zacks Equity Research

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why United Therapeutics (UTHR) is a Strong Momentum Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Here's Why United Therapeutics (UTHR) is a Strong Growth Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Here's Why United Therapeutics (UTHR) is a Strong Value Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag

by Zacks Equity Research

Allogene (ALLO) reports drab first-quarter 2024 results. The company secures the development and marketing rights to its CD19 oncology program in Europe.

Zacks Equity Research

Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates

by Zacks Equity Research

Insmed (INSM) Q1 earnings beat estimates while sales miss the mark. Management posts positive data readouts from mid-stage studies on its experimental inhalation powder in PH-ILD and PAH indications.

Zacks Equity Research

Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates

by Zacks Equity Research

Iovance (IOVA) reports mixed first-quarter results. Shares gain on encouraging initial demand for the recently-approved melanoma drug Amtagvi in the United States.

Zacks Equity Research

CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss

by Zacks Equity Research

CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.

Zacks Equity Research

Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues

by Zacks Equity Research

Esperion's (ESPR) first-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.

Zacks Equity Research

Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil

by Zacks Equity Research

Rocket Pharmaceuticals' (RCKT) first-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.

Zacks Equity Research

Perrigo (PRGO) Q1 Earnings Surpass, Sales Miss Estimates

by Zacks Equity Research

Perrigo (PRGO) reports mixed first-quarter 2024 results. Management reiterates its financial outlook for 2024.

Zacks Equity Research

Best Momentum Stock to Buy for May 7th

by Zacks Equity Research

LDOS, FCBC and UTHR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 7, 2024.

Zacks Equity Research

Best Value Stocks to Buy for May 7th

by Zacks Equity Research

UTHR and NWPX made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 7, 2024.

Zacks Equity Research

United Therapeutics (UTHR) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

United Therapeutics (UTHR) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

Here's Why United Therapeutics (UTHR) is a Strong Growth Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

United Therapeutics Corporation (UTHR) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

United Therapeutics (UTHR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales

by Zacks Equity Research

United Therapeutics' (UTHR) first-quarter 2024 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.

Zacks Equity Research

Compared to Estimates, United Therapeutics (UTHR) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

What Makes United Therapeutics (UTHR) a New Buy Stock

by Zacks Equity Research

United Therapeutics (UTHR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.